Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment
Open Access
- 25 July 2018
- journal article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 24 (12), e26-e30
- https://doi.org/10.1016/j.bbmt.2018.07.032
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuriaBlood, 2014
- Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromesEuropean Journal of Haematology, 2014
- Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2013
- Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomeraseBlood, 2013
- How I treat acquired aplastic anemiaBlood, 2012
- How I treat paroxysmal nocturnal hemoglobinuriaBlood, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Clinical Significance of a Small Population of Paroxysmal Nocturnal Hemoglobinuria-Type Cells in the Management of Bone Marrow FailureInternational Journal of Hematology, 2006
- Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemiaBlood, 2006
- Aplastic anaemiaThe Lancet, 2005